| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
5-LOX
The primary target of 3-O-Acetyl-11-hydroxy-beta-boswellic acid is 5-lipoxygenase (5-LO), a key enzyme in the biosynthesis of leukotrienes, which are potent inflammatory mediators. By inhibiting 5-LO, the compound reduces the production of leukotrienes, thereby exerting anti-inflammatory effects. This mechanism is distinct from that of traditional NSAIDs, which primarily target cyclooxygenase (COX) enzymes. |
|---|---|
| ln Vitro |
In vitro, 3-O-Acetyl-11-hydroxy-beta-boswellic acid is a potent inhibitor of 5-lipoxygenase (5-LO). It is the precursor of 3-O-acetyl-9,11-dehydro-beta-boswellic acid, which is also a 5-LO inhibitor. Its inhibitory activity against 5-LO contributes to its anti-inflammatory properties, making it a valuable tool for studying the role of leukotrienes in inflammation.
|
| ln Vivo |
In vivo, 3-O-Acetyl-11-hydroxy-beta-boswellic acid may have anti-inflammatory effects through its inhibition of 5-LO. As a natural product from Boswellia serrata, it contributes to the overall anti-inflammatory activity of frankincense extracts. However, detailed in vivo efficacy data are not extensively reported in the available literature.
|
| Enzyme Assay |
In vitro enzyme assays for 3-O-Acetyl-11-hydroxy-beta-boswellic acid involve measuring the inhibition of 5-lipoxygenase (5-LO) activity. The enzyme is incubated with arachidonic acid as a substrate in the presence of varying concentrations of the compound. The production of leukotrienes is measured, and the IC50 value is determined from the concentration-response curve.
|
| Cell Assay |
In vitro cellular assays for this compound may involve the use of inflammatory cells, such as leukocytes, to assess its effects on leukotriene production. Cells are stimulated with calcium ionophore or other agents, and the production of leukotrienes is measured in the presence of the compound.
|
| Animal Protocol |
In vivo animal studies for 3-O-Acetyl-11-hydroxy-beta-boswellic acid would typically involve the administration of the compound to rodent models of inflammation. Its effects on inflammatory markers and leukotriene levels would be assessed.
|
| ADME/Pharmacokinetics |
3-O-Acetyl-11-hydroxy-beta-boswellic acid has a molecular weight of 514.74 and a molecular formula of C32H50O5. It is a solid powder with a purity of ≥98%. It is typically stored dry, in the dark, at -20°C for up to 1 year. Detailed pharmacokinetic parameters are not available.
|
| Toxicity/Toxicokinetics |
There is no specific toxicity data reported for this compound. As a research chemical, it should be handled with standard safety precautions.
|
| References | |
| Additional Infomation |
According to reports, Boswellia sacra contains 3-O-acetyl-11-hydroxy-β-boswellic acid, and there is relevant data.
3-O-Acetyl-11-hydroxy-beta-boswellic acid (Ac-11-OH-BA) is a pentacyclic triterpenoid and a potent 5-lipoxygenase inhibitor. It has a molecular formula of C32H50O5 and a molecular weight of 514.74. It is a precursor of another 5-LO inhibitor and is used in research to study anti-inflammatory pathways. |
| Molecular Formula |
C32H50O5
|
|---|---|
| Molecular Weight |
514.74
|
| Exact Mass |
514.365
|
| CAS # |
146019-25-2
|
| PubChem CID |
134715236
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
160-162 °C
|
| LogP |
7.2
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
37
|
| Complexity |
1020
|
| Defined Atom Stereocenter Count |
12
|
| SMILES |
C[C@@H]1CC[C@@]2(CC[C@@]3(C(=C[C@H]([C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@H]([C@]5(C)C(=O)O)OC(=O)C)C)C)O)[C@@H]2[C@H]1C)C)C
|
| InChi Key |
GKZSILIAFXNPRA-GHQZQFNUSA-N
|
| InChi Code |
InChI=1S/C32H50O5/c1-18-9-12-28(4)15-16-30(6)21(25(28)19(18)2)17-22(34)26-29(5)13-11-24(37-20(3)33)32(8,27(35)36)23(29)10-14-31(26,30)7/h17-19,22-26,34H,9-16H2,1-8H3,(H,35,36)/t18-,19+,22-,23-,24-,25+,26-,28-,29+,30-,31-,32-/m1/s1
|
| Chemical Name |
(3R,4R,4aR,6aR,6bS,8aR,11R,12S,12aR,14R,14aR,14bS)-3-acetyloxy-14-hydroxy-4,6a,6b,8a,11,12,14b-heptamethyl-2,3,4a,5,6,7,8,9,10,11,12,12a,14,14a-tetradecahydro-1H-picene-4-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 125 mg/mL (242.84 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.04 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.04 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9427 mL | 9.7136 mL | 19.4273 mL | |
| 5 mM | 0.3885 mL | 1.9427 mL | 3.8855 mL | |
| 10 mM | 0.1943 mL | 0.9714 mL | 1.9427 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
